21:34 , May 8, 2019 |  BC Extra  |  Financial News

CRO Viva raises $193.9 million in Hong Kong IPO

Viva will begin trading Thursday after raising HK$1.5 billion (US$193.9 million) early Wednesday in an IPO that values the drug discovery services company at HK$6.6 billion (US$843.1 million). Viva Biotech Holdings (HKSE:1873) sold 345 million...
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
21:05 , Mar 15, 2019 |  BioCentury  |  Finance

HaiHe's listing recipe

While a recent mega-round raised by HaiHe could position the Shanghai-based company to go public this year, lead investor Huagai Capital is not looking for an exit at least until the company’s first products hit...
02:38 , Feb 28, 2019 |  BC Week In Review  |  Clinical News

China approves first biosimilar, Shanghai Henlius’ HLX01

China's National Medical Products Administration (NMPA) approved the country’s first biosimilar, rituximab biosimilar HLX01 from Shanghai Henlius Biotech Inc. (Shanghai, China). The chimeric mAb against CD20 was approved in China for the same indications as...
23:45 , Feb 25, 2019 |  BC Extra  |  Company News

China approves first biosimilar, Shanghai Henlius’ HLX01

China's National Medical Products Administration (NMPA) approved last Friday the country’s first biosimilar, rituximab biosimilar HLX01 from Shanghai Henlius Biotech Inc. (Shanghai, China). The chimeric mAb against CD20 was approved in China for the same...
01:03 , Jan 12, 2019 |  BioCentury  |  Finance

Warning: cash needed

  A near decade-long run of cheap money appears to be coming to a close, and most of the biotech sector isn’t well positioned for the new reality. BioCentury’s analysis shows that two-thirds of biotech...
20:14 , Dec 21, 2018 |  BC Week In Review  |  Financial News

Shanghai Henlius up for Hong Kong IPO

Biosimilars company Shanghai Henlius Biotech Inc. (Shanghai, China) proposed on Dec. 14 to list on the Hong Kong stock exchange. Shanghai Henlius' lead compound is HLX01, a biosimilar of cancer and autoimmune drug MabThera rituximab...
00:06 , Dec 15, 2018 |  BC Extra  |  Financial News

Shanghai Henlius up for Hong Kong IPO

Biosimilars company Shanghai Henlius Biotech Inc. (Shanghai, China) proposed on Friday to list on the Hong Kong stock exchange. Shanghai Henlius' lead compound is HLX01, a biosimilar of cancer and autoimmune drug MabThera rituximab from...
19:26 , Sep 28, 2018 |  BC Week In Review  |  Financial News

Shanghai Henlius to move forward with Hong Kong listing

Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKSE:2196) said on Sept. 27 its board approved a resolution to list Shanghai Henlius Biotech Inc. (Shanghai, China) on the Hong Kong stock exchange. Shanghai Henlius, a JV...
22:19 , Mar 16, 2018 |  BioCentury  |  Finance

Hong Kong’s new chapter

Introducing a biotech chapter to the Hong Kong stock exchange fills a massive void in the region’s innovation ecosystem, but won’t come without risks. It promises to create a long sought public capital market for...